8-K: Nutriband and Kindeva Sign Commercial Agreement for Abuse-Deterrent Fentanyl Patch

Nutriband has entered into a commercial agreement with Kindeva Drug Delivery to develop and manufacture their Aversa abuse-deterrent fentanyl patch.

Summary

• Nutriband has signed a commercial development and clinical supply agreement with Kindeva Drug Delivery for their Aversa Fentanyl patch.
• Kindeva will handle commercial manufacturing process development and produce clinical supplies for the required human abuse liability study.
• This agreement replaces a previous feasibility agreement between the two companies.
• Aversa Fentanyl combines Nutriband's abuse-deterrent technology with Kindeva's transdermal fentanyl patch system.
• The Aversa Fentanyl patch is estimated to have a potential peak annual US sales of $80M to $200M.
• Nutriband's Aversa technology aims to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the commercial agreement, the potential market size, and the partnership with a reputable CDMO. However, the risks associated with drug development and regulatory approvals temper the overall optimism.

Positives

• The commercial agreement with Kindeva is a significant step towards commercializing Aversa Fentanyl.
• The partnership leverages Kindeva's expertise in transdermal drug delivery.
• Aversa technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse.
• The Aversa Fentanyl patch has a substantial market potential with estimated peak annual US sales of $80M to $200M.
• The technology is protected by a broad intellectual property portfolio.

Risks

• The company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products is not guaranteed.
• Obtaining patent protection for its abuse technology is not guaranteed.
• The company's ability to obtain the necessary financing to develop products and conduct the necessary clinical testing is not guaranteed.
• Obtaining FDA approval to market any product in the United States and other regulatory approvals in other countries is not guaranteed.
• The company's ability to market any product it may develop is not guaranteed.
• The company's ability to create, sustain, manage or forecast its growth is not guaranteed.
• The company's ability to attract and retain key personnel is not guaranteed.
• Changes in the company's business strategy or development plans could impact the company.
• Competition, business disruptions, and adverse publicity could impact the company.
• International, national and local general economic and market conditions could impact the company.
• Risks generally associated with an undercapitalized developing company could impact the company.

Future Outlook

The company aims to rapidly commercialize Aversa Fentanyl and capitalize on its significant market potential. The company's future success depends on various factors including the ability to obtain regulatory approvals and secure financing.

Management Comments

• Gareth Sheridan, CEO of Nutriband, stated that Aversa technology has the potential to improve the safety profile of transdermal drugs while ensuring access for patients who need them.
• David Stevens, Global Chief Commercial Officer of Kindeva, highlighted Kindeva's expertise in transdermal capabilities and their appreciation for Nutriband's partnership.

Industry Context

This announcement highlights the growing focus on developing abuse-deterrent formulations for opioid medications, particularly in the transdermal patch market. It reflects a broader industry trend towards safer drug delivery systems.

Comparison to Industry Standards

• The development of abuse-deterrent opioid patches is a key area of focus in the pharmaceutical industry, with companies like Teva and Purdue Pharma also working on similar technologies.
• The estimated peak annual sales of $80M to $200M for Aversa Fentanyl is a significant market opportunity, but will depend on successful clinical trials and regulatory approvals.
• Kindeva is a well-established CDMO with a strong track record in transdermal drug delivery, which positions Nutriband well for commercialization.

Stakeholder Impact

• Shareholders may view this agreement positively due to the potential for future revenue.
• Patients could benefit from a safer opioid patch with abuse-deterrent properties.
• Employees may see this as a positive step for the company's growth.
• Kindeva will benefit from the manufacturing contract.

Next Steps

• Kindeva will perform commercial manufacturing process development.
• Kindeva will manufacture clinical supplies for the human abuse liability clinical study.
• Nutriband will pursue FDA approval for the Aversa Fentanyl patch.

Key Dates

Keywords

Aversa Fentanyl, transdermal patch, abuse-deterrent, Kindeva Drug Delivery, fentanyl, pharmaceutical, drug delivery, commercialization, clinical study, FDA, opioid